Ai-Media Technologies Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 610
- Market Cap
- $20.9M
- Introduction
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HUTCHMED divests 45% equity in Shanghai Hutchison Pharmaceuticals for ~US$608M to focus on core innovative medicines, including advancing its antibody-targeted therapy conjugate platform, with clinical trials expected in late 2025.
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate ...
Vote FOR Kellner Group nominees to bring change to AIM Immunotech's Board, as the incumbent Board has failed stockholders. Kellner Group, owning 5.04% of shares, denies short selling allegations and aims to create value for all stockholders.
Four investment experts identify eight healthcare investments beyond obesity drugs
Innovations in obesity, ovarian cancer vaccines, Alzheimer’s, and mental health drugs are transforming healthcare, with UK tech stocks and biotech sectors offering untapped investment opportunities. Key players include Intra-Cellular Therapies, Supernus Pharmaceuticals, and specialist providers like Bioventix and Diaceutics. Funds like Comgest Growth Europe ex UK and Polar Capital Global Healthcare Trust offer diversified healthcare exposure.
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type
New TNBC treatment at Roswell Park achieves 66% complete remission without immune-related adverse events, using a combination of chemotherapy and immunotherapy.
Issue of Equity and Total Voting Rights
Avacta Therapeutics issues 5,930,659 new ordinary shares to settle £2.55m principal and £0.54m interest on convertible bond, reducing remaining principal to £30.60m. The bond was initially issued in Oct 2022 to fund acquisitions and working capital, with the company now focusing on drug development. The new shares are expected to be admitted to trading on AIM on 23 Oct 2024, increasing total issued share capital to 369,306,389.
NYC COVID czar reveals he pushed monkeypox drug despite 'very low' risk to public
Jay Varma, former NYC Mayor’s Office Senior Advisor for Public Health, admitted to pushing monkeypox drug TPOXX despite low risk to the general public, focusing on gay men. Varma aimed to get FDA approval for TPOXX, leveraging media to maintain public belief in the drug's efficacy.
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Takeda receives approval from the Japanese Ministry of Health, Labour and Welfare for FRUZAQLA® (fruquintinib) for previously treated metastatic colorectal cancer, based on results from the global Phase III FRESCO-2 trial. FRUZAQLA® is the first novel targeted therapy approved in Japan for metastatic CRC in over a decade.
R&D for long COVID is collapsing
Lack of funding and understanding of long COVID's mechanisms hinder drug development, frustrating patients and researchers. Despite initial positive results with Ampligen, Aim ImmunoTech faced funding challenges. The NIH's RECOVER initiative focuses on observational studies rather than new compounds, and private investors avoid long COVID due to perceived risk. Small biotech companies struggle to sustain research efforts, with some shifting focus or shutting down. Public-private partnerships and increased federal funding are suggested as solutions to advance long COVID treatment research.
hVIVO PLC (AIM:HVO) Interim results - Strong first half delivering record revenues and margins
hVIVO achieved record H1 revenues of £35.6m, up 30.6% from H1 2023, driven by operational efficiencies and a new facility in Canary Wharf. The company secured a £71m weighted orderbook and expanded its service offerings, including new revenue streams and automation at FluCamp. hVIVO reaffirmed its full-year revenue guidance of £62m and targets £100m by 2028.
© Copyright 2025. All Rights Reserved by MedPath